Matinas BioPharma (MTNB) News Today

$0.18
0.00 (-0.44%)
(As of 12:05 PM ET)
SourceHeadline
msn.com logoMatinas Declines on Public Offering
msn.com - April 3 at 1:52 PM
globenewswire.com logoMatinas BioPharma Prices $10 Million Registered Direct Offering
globenewswire.com - April 3 at 8:30 AM
finance.yahoo.com logoMatinas BioPharma Holdings, Inc. (AMEX:MTNB) Q4 2023 Earnings Call Transcript
finance.yahoo.com - April 1 at 3:38 PM
finanznachrichten.de logoMatinas BioPharma Holdings, Inc.: Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update
finanznachrichten.de - March 28 at 5:11 PM
marketbeat.com logoMatinas BioPharma (NYSEAMERICAN:MTNB) Issues Earnings Results
marketbeat.com - March 28 at 9:18 AM
finance.yahoo.com logoQ4 2023 Matinas BioPharma Holdings Inc Earnings Call
finance.yahoo.com - March 28 at 7:33 AM
investorplace.com logoMTNB Stock Earnings: Matinas BioPharma Hldgs Reported Results for Q4 2023
investorplace.com - March 27 at 11:03 PM
globenewswire.com logoMatinas BioPharma Reports 2023 Financial Results and Provides a Business Update
globenewswire.com - March 27 at 4:05 PM
finanznachrichten.de logoMatinas BioPharma Holdings, Inc.: Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation
finanznachrichten.de - March 25 at 10:12 AM
globenewswire.com logoMatinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation
globenewswire.com - March 25 at 8:00 AM
finance.yahoo.com logoWhy Is Fungal Infections-Focused Matinas BioPharma Stock Trading Higher On Friday?
finance.yahoo.com - March 22 at 3:59 PM
finance.yahoo.com logoThree Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response
finance.yahoo.com - March 22 at 10:59 AM
globenewswire.com logoThree Patients with Invasive Fusarium Infection in Matinas BioPharma's Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response
globenewswire.com - March 22 at 9:15 AM
globenewswire.com logoMatinas BioPharma Regains Compliance with NYSE American Continued Listing Standards
globenewswire.com - March 22 at 6:30 AM
marketbeat.com logoMatinas BioPharma (MTNB) to Release Quarterly Earnings on Wednesday
marketbeat.com - March 12 at 7:35 AM
uk.finance.yahoo.com logoMatinas BioPharma Holdings, Inc. (MTNB)
uk.finance.yahoo.com - March 3 at 12:03 AM
wsj.com logoMatinas BioPharma Holdings Inc.
wsj.com - February 28 at 7:49 AM
finance.yahoo.com logoMatinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution
finance.yahoo.com - February 26 at 8:27 AM
benzinga.com logoMatinas BioPharma Hldgs Stock (AMEX:MTNB) Dividends: History, Yield and Dates
benzinga.com - February 23 at 7:18 AM
finance.yahoo.com logoMatinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis
finance.yahoo.com - February 20 at 8:14 AM
globenewswire.com logoMatinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis
globenewswire.com - February 20 at 7:30 AM
seekingalpha.com logoAVBP ArriVent BioPharma, Inc.
seekingalpha.com - February 4 at 7:38 AM
morningstar.com logoMatinas BioPharma Holdings Inc MTNB
morningstar.com - January 21 at 3:21 AM
finance.yahoo.com logoMatinas BioPharma to Present at Biotech Showcase 2024
finance.yahoo.com - January 3 at 8:41 AM
finance.yahoo.com logoMatinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides
finance.yahoo.com - December 27 at 8:07 AM
finanznachrichten.de logoMatinas BioPharma Holdings, Inc.: Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDA
finanznachrichten.de - December 21 at 9:15 AM
markets.businessinsider.com logoMatinas BioPharma Plans To Meet With FDA In Q1 To Finalize Phase 3 Protocol For MAT2203
markets.businessinsider.com - December 21 at 8:25 AM
finance.yahoo.com logoMatinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDA
finance.yahoo.com - December 21 at 8:25 AM
benzinga.com logoMatinas BioPharma Hldgs Stock (AMEX:MTNB), Guidance and Forecast
benzinga.com - December 20 at 11:55 PM
markets.businessinsider.com logoAnalysts Offer Insights on Healthcare Companies: Bolt Biotherapeutics (BOLT), Matinas BioPharma (MTNB) and Vor Biopharma (VOR)
markets.businessinsider.com - November 11 at 12:29 AM
markets.businessinsider.com logoAnalysts Offer Insights on Healthcare Companies: Athira Pharma (ATHA), Shattuck Labs (STTK) and Matinas BioPharma (MTNB)
markets.businessinsider.com - November 10 at 7:53 PM
finance.yahoo.com logoMatinas BioPharma Holdings, Inc. (AMEX:MTNB) Q3 2023 Earnings Call Transcript
finance.yahoo.com - November 10 at 2:20 PM
finance.yahoo.com logoQ3 2023 Matinas BioPharma Holdings Inc Earnings Call
finance.yahoo.com - November 9 at 9:22 AM
finance.yahoo.com logoMatinas BioPharma Holdings Inc (MTNB) Reports Q3 2023 Financial Results and Business Progress
finance.yahoo.com - November 8 at 7:34 PM
finance.yahoo.com logoMatinas BioPharma Reports Third Quarter 2023 Financial Results and Provides a Business Update
finance.yahoo.com - November 8 at 5:54 PM
finanznachrichten.de logoMatinas BioPharma Holdings, Inc.: Matinas BioPharma Announces Positive in vivo Efficacy Results of Oral LNC Docetaxel Formulation in a Melanoma Model
finanznachrichten.de - November 7 at 8:17 AM
finance.yahoo.com logoMatinas BioPharma Announces Positive in vivo Efficacy Results of Oral LNC Docetaxel Formulation in a Melanoma Model
finance.yahoo.com - November 7 at 8:17 AM
finance.yahoo.com logoMatinas BioPharma to Webcast Conference Call to Discuss Third Quarter 2023 Financial Results and Provide a Business Update on November 8, 2023
finance.yahoo.com - November 1 at 8:00 AM
msn.com logoBTIG Reiterates Matinas Biopharma Holdings (MTNB) Buy Recommendation
msn.com - October 13 at 7:36 AM
marketwatch.com logoMatinas BioPharma Shares Double After Patient Achieves Clinical Resolution
marketwatch.com - October 11 at 2:28 PM
theglobeandmail.com logoBiotech Catches Massive Premarket Bid
theglobeandmail.com - October 11 at 2:28 PM
msn.com logoMatinas BioPharma stock soars 80% on antifungal drug update
msn.com - October 11 at 11:52 AM
finance.yahoo.com logoPatient with Candida krusei Infection in Matinas BioPharma’s Oral MAT2203 Expanded Access Program Achieves Complete Clinical Resolution
finance.yahoo.com - October 11 at 7:58 AM
finance.yahoo.com logoMatinas BioPharma to Present at Two Investment Conferences in October 2023
finance.yahoo.com - September 28 at 7:36 AM
finance.yahoo.com logoMatinas BioPharma to Feature MAT2203 in a Pipeline Presentation at IDWeek
finance.yahoo.com - September 27 at 8:23 AM
finanznachrichten.de logoMatinas BioPharma Holdings, Inc.: Matinas BioPharma Announces Notification of NYSE American Continued Listing Deficiency
finanznachrichten.de - September 23 at 7:00 AM
finance.yahoo.com logoMatinas BioPharma Announces Notification of NYSE American Continued Listing Deficiency
finance.yahoo.com - September 22 at 5:37 PM
finance.yahoo.com logoMatinas BioPharma to Participate in the H.C. Wainwright Global Investment Conference
finance.yahoo.com - September 6 at 7:38 AM
finance.yahoo.com logoMatinas BioPharma Announces Publication of Results from the Phase 2 EnACT Clinical Trial of MAT2203 in the IDSA Journal Clinical Infectious Diseases
finance.yahoo.com - August 22 at 7:41 AM
finanznachrichten.de logoMatinas BioPharma Holdings, Inc.: Matinas BioPharma Reports Second Quarter 2023 Financial Results and Provides a Business Update
finanznachrichten.de - August 11 at 4:00 PM
Get Matinas BioPharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for MTNB and its competitors with MarketBeat's FREE daily newsletter.

$25,000 into $109,616 in two months? (Ad)

Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…

Go here to watch the most recent trading workshop video at no charge.

MTNB Media Mentions By Week

MTNB Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

MTNB
News Sentiment

0.00

0.44

Average
Medical
News Sentiment

MTNB News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

MTNB Articles
This Week

0

1

MTNB Articles
Average Week

Get Matinas BioPharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for MTNB and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NYSEAMERICAN:MTNB) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners